Abbott (NYSE:ABT) said today it won FDA premarket approval for its iDesign Advanced WaveScan studio system designed to generate high-definition eye scans used for Lasik surgery. The system’s sensor technology, developed by Abbott, is also being used by NASA in the James Webb Space Telescope, slated to launch in 2018, Chicago-based Abbott said. “The iDesign […]
Optical/Ophthalmic
Valeant Pharma to acquire contact maker Unilens for $28m
Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) said today it entered into an agreement to acquire Unilens Vision for $28 million, including $5 million in debt. Under the agreement, which was unanimously approved by Largo, Fla.-based Unilens’ board of directors, a wholly-owned subsidiary of Valeant will acquire Unilens for $12.75 per share in cash. “We are very pleased […]
Tilting Capital plans reverse merger with ArcScan
Canadian venture group Tilting Capital said last week that it’s planning a reverse merger with Golden, Colo.-based ophthalmic imaging device developer ArcScan. Tilting Capital said it agreed to put up about $7.2 million (Cdn $9.2 million) worth of its own stock, or 61.4 million shares, valued at 12¢ (Cdn 15¢) apiece, in a 1-for-1 trade with ArcScan stockowners. The […]
Allergan to drop $125m on Oculeve
Allergan (NYSE:AGN) said today that it agreed to pay $125 million up front to acquire Oculeve and its dry eye disease device program, plus unspecified commercialization milestones. South San Francisco-based Oculeve is developing a product called OD-01, a non-invasive nasal neurostimulation device designed to increase tear production in patients with dry eye disease, Allergan said. A pair […]
Alcon wins CE Mark for AcrySof IQ PanOptix trifocal lens
Alcon said last month that it won CE Mark approval in the European Union for its AcrySof IQ PanOptix trifocal intraocular lens. The lens is indicated for use in patients undergoing cataract surgery who need treatment for near, intermediate, and distance vision needs with a single lens, the Switzerland-based company said. “The AcrySof IQ PanOptix trifocal IOL […]
Glaukos closes $140m IPO, puts up $26m for Dose Medical affiliate
Glaukos (NYSE:GKOS) yesterday said it closed its $140 million initial public offering with it underwriters exercising their over-allotment option, meaning net proceeds for the glaucoma device maker of roughly $112.3 million. Laguna Hills, Calif.-based Glaukos said J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. acted as joint book-running managers, with William Blair and Cantor Fitzgerald […]
Glaukos prices $108m IPO above the range
Glaukos yesterday said it priced its initial public offering at $18 per share, above its previously announced range, for total proceeds of $108 million. The 6-million-share offering includes an underwriters over-allotment option of another 900,000 shares, the Laguna Hills, Calif.-based company said. Glaukos initially said the offering could gross as much as $86.2 million. Earlier this […]
Second Sight touts 3-year Argus II retinal prosthesis data
Second Sight Medical (NSDQ:EYES) said data from a 3-year study of its Argus II retinal prosthesis system show positive results in previously blind patients. The study, published in Ophthalmology yesterday, examined 30 patients implanted with the Argus II, designed to restore partial vision by stimulating viable retinal cells in patients with severe to profound retinitis pigmentosa, […]
Glaukos raises the stakes in $99m IPO
Glaukos today raised the proposed price range on its pending initial public offering, saying it will offer 6 million shares at $16 to $17 apiece, which at the midpoint would fetch $99.0 million. In May, Laguna Hills, Calif.-based Glaukos initially said the offering could gross as much as $86.2 million. Earlier this month the company said it planned […]
Glaukos sets terms for $75m IPO
Glaukos today set the terms for its pending initial public offering, saying it plans to float nearly 5.4 million shares at $13 to $15 apiece. At the midpoint of the range, the IPO would fetch $75.0 million. Laguna Hills, Calif.-based Glaukos initially said the offering could gross as much as $86.2 million. The IPO also includes […]
Calhoun Vision raises $69m for ‘adjustable’ IOL
Calhoun Vision said today that it raised a $69 million funding round for its ‘light-adjustable’ intra-ocular lens, with $52 million coming from a new round of financing and $17 million in a debt conversion. The round was led by Longitude Capital, with H.I.G. BioVentures, Balance Point Capital Partners, and RA Capital Management as co-investors. “This […]